A Phase 2 interventional study of SPI-2012 and Pegfilgrastim in Neutropenia, sponsored by Spectrum Pharmaceuticals, Inc. Completed at 27 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-04-15.
Sponsored by Spectrum Pharmaceuticals, Inc (part of Zydus Lifesciences Limited) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies testing pegfilgrastim in Neutropenia — none open to participants now, none under way, none of them phase 3. pegfilgrastim · Neutropenia.
Among the 33 studies testing pegfilgrastim in Neutropenia, this one is the 13th largest by enrollment of the 28 interventional ones that give a count, is one of 2 that started in 2013, is one of 14 in phase 2, and was the 21st registered.
316 studies on the registry are indexed under Neutropenia; 42 are open to participants now.
Browse Neutropenia studies →None of the 33 studies testing pegfilgrastim in Neutropenia is open now. The open studies under Neutropenia, anywhere →
pegfilgrastim: first FDA approval 2002 (NEULASTA), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 24 Neutropenia studies recruiting now, 12 (50%) set no upper age limit and 12 (50%) stop at 75 or younger; 11 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 15 · Phase 3 12 · Phase 4 3
First in 2000; this study’s year is marked. 2 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 148 is above the median of 82 across 230 interventional studies indexed under Neutropenia.
Median enrollment 121 across the 28 interventional studies. Of the 28 that completed or were terminated, 5 (18%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 33 have an industry lead sponsor. The 10 most frequent:
This study is registered under Spectrum Pharmaceuticals, Inc, one of the names counted as Zydus Lifesciences Limited. Under that name alone:
Spectrum Pharmaceuticals, Inc is the lead sponsor of 60 studies on the registry; 1 is open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 12 (67%) have results posted.
Zydus Lifesciences Limited has 4 studies filed under Neutropenia — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 33 studies testing pegfilgrastim in Neutropenia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the effect of test doses of SPI-2012 on the duration of severe neutropenia (DSN) during Cycle 1 in participants with breast cancer who are candidates for adjuvant or neoadjuvant chemotherapy.
This is an open label, multicenter, dose ranging study, sequentially enrolled by study dose, with a non-inferiority design to compare the effectiveness of SPI-2012 relative to a fixed dose of pegfilgrastim as a concurrent active control to each dose of SPI-2012 in participants with breast cancer. This study included four arms comprising three dose levels of SPI-2012 (Arm 1: 45 µg/kg, Arm 2: 135 µg/kg, Arm 3: 270 µg/kg) versus pegfilgrastim (Arm 4: 6 mg). The start of study is defined as the initiation of treatment with SPI-2012 or pegfilgrastim. The duration of treatment consists of a maximum of 4 cycles (21 days per cycle) beginning on Day 1 with chemotherapy administration and continue through Day 21, plus a 30-day follow-up period, unless any of the discontinuation criteria applies.
The target population are participants with breast cancer who are candidates for neoadjuvant or adjuvant treatment with Docetaxel + Cyclophosphamide (TC) chemotherapy. All participants who receive at least 1 dose of either SPI-2012 or pegfilgrastim were followed for safety through 30 days after their last dose of study treatment or until all treatment-related adverse events (AEs) have resolved or returned to baseline/Grade 1, whichever is longer, or until it is determined that the outcome will not change with further follow-up.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received SPI-2012 45 microgram/kilogram (µg/kg), subcutaneously (SC) once per cycle on Day 2 of each cycle up to cycle 4 (each cycle was 21 days), approximately 24 hours after the administration of TC chemotherapy. TC chemotherapy was administered on Day 1 of each cycle as follows: Docetaxel 75 milligram/ square metre (mg/m\^2) intravenous (IV) infusion over 60 minutes and Cyclophosphamide 600 mg/m\^2 IV infusion over 30-60 minutes.
Drug: SPI-2012 · Drug: Docetaxel · Drug: Cyclophosphamide
Participants received SPI-2012 135 µg/kg, SC once per cycle on Day 2 of each cycle up to cycle 4 (each cycle was 21 days), approximately 24 hours after the administration of TC chemotherapy. TC chemotherapy was administered on Day 1 of each cycle as follows: Docetaxel 75 mg/m\^2 intravenous (IV) infusion over 60 minutes and Cyclophosphamide 600 mg/m\^2 IV infusion over 30-60 minutes.
Drug: SPI-2012 · Drug: Docetaxel · Drug: Cyclophosphamide
Participants received SPI-2012 270 µg/kg, SC once per cycle on Day 2 of each cycle up to cycle 4 (each cycle was 21 days), approximately 24 hours after the administration of TC chemotherapy. TC chemotherapy was administered on Day 1 of each cycle as follows: Docetaxel 75 mg/m\^2 intravenous (IV) infusion over 60 minutes and Cyclophosphamide 600 mg/m\^2 IV infusion over 30-60 minutes.
Drug: SPI-2012 · Drug: Docetaxel · Drug: Cyclophosphamide
Participants received Pegfilgrastim 6 milligram (mg), SC once per cycle on Day 2 of each cycle up to cycle 4 (each cycle was 21 days), approximately 24 hours after the administration of TC chemotherapy. TC chemotherapy was administered on Day 1 of each cycle as follows: Docetaxel 75 mg/m\^2 intravenous (IV) infusion over 60 minutes and Cyclophosphamide 600 mg/m\^2 IV infusion over 30-60 minutes.
Drug: Pegfilgrastim · Drug: Docetaxel · Drug: Cyclophosphamide
SPI-2012 SC injection.
Also known as: Rolontis®, HM10460A, Eflapegrastim
Pegfilgrastim SC injection, per manufacturer's Prescribing Information.
Also known as: Neulasta®
Docetaxel given based on standard dose for chemotherapy.
Also known as: Taxotere
Cyclophosphamide given based on standard dose for chemotherapy.
Also known as: Cytoxan
Duration of Severe Neutropenia (DSN) in Cycle 1
DSN was defined as the interval from the day of first observation of severe neutropenia (ANC \<0.5\*10\^9/L, Grade 4 neutropenia per NCI CTCAE) to the first ANC recovery to =\> 2.0\*10\^9/L in Cycle 1.
Time frame: Cycle 1 (each cycle was 21 days)
Duration of DSN in Cycle 2
DSN was defined as the interval from the day of first observation of severe neutropenia (ANC \<0.5\*10\^9/L, Grade 4 neutropenia per NCI CTCAE) to the first ANC recovery to =\> 2.0\*10\^9/L in Cycle 2.
Time frame: Cycle 2 (each cycle was 21 days)
Duration of DSN in Cycle 3
DSN was defined as the interval from the day of first observation of severe neutropenia (ANC \<0.5\*10\^9/L, Grade 4 neutropenia per NCI CTCAE) to the first ANC recovery to =\> 2.0\*10\^9/L in Cycle 3.
Time frame: Cycle 3 (each cycle was 21 days)
Duration of DSN in Cycle 4
DSN was defined as the interval from the day of first observation of severe neutropenia (ANC \<0.5\*10\^9/L, Grade 4 neutropenia per NCI CTCAE) to the first ANC recovery to =\> 2.0\*10\^9/L in Cycle 4.
Time frame: Cycle 4 (each cycle was 21 days)
Time to ANC Recovery in Cycle 1
Time to ANC recovery was defined as the time from chemotherapy administration until ANC increased to ≥ 2×10\^9/L after the expected nadir within Cycle 1. Time to ANC recovery was not calculated for participants whose ANC value didn't drop below 2 x10\^9/L within Cycle 1.
Time frame: Cycle 1 (each cycle was 21 days)
Time to ANC Recovery in Cycle 2
Time to ANC recovery was defined as the time from chemotherapy administration until ANC increased to ≥2×10\^9/L after the expected nadir within Cycle 2. Time to ANC recovery was not calculated for participants whose ANC value didn't drop below 2 x10\^9/L within Cycle 2.
Time frame: Cycle 2 (each cycle was 21 days)
Time to ANC Recovery in Cycle 3
Time to ANC recovery was defined as the time from chemotherapy administration until ANC increased to ≥2×10\^9/L after the expected nadir within Cycle 3. Time to ANC recovery was not calculated for participants whose ANC value didn't drop below 2 x10\^9/L within Cycle 3.
Time frame: Cycle 3 (each cycle was 21 days)
Time to ANC Recovery in Cycle 4
Time to ANC recovery was defined as the time from chemotherapy administration until ANC increased to ≥2×10\^9/L after the expected nadir within Cycle 4. Time to ANC recovery was not calculated for participants whose ANC value didn't drop below 2 x10\^9/L within Cycle 4.
Time frame: Cycle 4 (each cycle was 21 days)
Absolute Neutrophil Count (ANC) Nadir Overtime in Cycle 1
Mean ANC nadir was defined as the mean of the lowest ANC value (\*10\^9/L) after administration of the study drug (SPI-2012 or pegfilgrastim) on any day in Days 1-3 of Cycle 1.
Time frame: Cycle 1 (each cycle was 21 days)
Absolute ANC Nadir Overtime in Cycle 2
Mean ANC nadir was defined as the mean of the lowest ANC value (\*10\^9/L) after administration of the study drug (SPI-2012 or pegfilgrastim) on any day in Days 1-3 of Cycle 2.
Time frame: Cycle 2 (each cycle was 21 days)
Absolute ANC Nadir Overtime in Cycle 3
Mean ANC nadir was defined as the mean of the lowest ANC value (\*10\^9/L) after administration of the study drug (SPI-2012 or pegfilgrastim) on any day in Days 1-3 of Cycle 3.
Time frame: Cycle 3 (each cycle was 21 days)
Absolute ANC Nadir Overtime in Cycle 4
Mean ANC nadir was defined as the mean of the lowest ANC value (\*10\^9/L) after administration of the study drug (SPI-2012 or pegfilgrastim) on any day in Days 1-3 of Cycle 4.
Time frame: Cycle 4 (each cycle was 21 days)
Depth of ANC Nadir in Cycle 1
Depth of ANC nadir was defined as the lowest Median ANC value (\*10\^9/L) after administration of the study drug (SPI-2012 or pegfilgrastim) on any day in Days 1-3 of Cycle 1.
Time frame: Cycle 1 (each cycle was 21 days)
Depth of ANC Nadir in Cycle 2
Depth of ANC nadir was defined as the lowest Median ANC value (\*10\^9/L) after administration of the study drug (SPI-2012 or pegfilgrastim) on any day in Days 1-3 of Cycle 2.
Time frame: Cycle 2 (each cycle was 21 days)
Depth of ANC Nadir in Cycle 3
Depth of ANC nadir was defined as the lowest Median ANC value (\*10\^9/L) after administration of the study drug (SPI-2012 or pegfilgrastim) on any day in Days 1-3 of Cycle 3.
Time frame: Cycle 3 (each cycle was 21 days)
Depth of ANC Nadir in Cycle 4
Depth of ANC nadir was defined as the lowest Median ANC value (\*10\^9/L) after administration of the study drug (SPI-2012 or pegfilgrastim) on any day in Days 1-3 of Cycle 4.
Time frame: Cycle 4 (each cycle was 21 days)
Time to ANC Nadir in Cycle 1
Time to ANC nadir was defined as the time from chemotherapy administration until the occurrence of the ANC nadir.
Time frame: Cycle 1 (each cycle was 21 days)
Time to ANC Nadir in Cycle 2
Time to ANC nadir was defined as the time from chemotherapy administration until the occurrence of the ANC nadir.
Time frame: Cycle 2 (each cycle was 21 days)
Time to ANC Nadir in Cycle 3
Time to ANC nadir was defined as the time from chemotherapy administration until the occurrence of the ANC nadir.
Time frame: Cycle 3 (each cycle was 21 days)
Time to ANC Nadir in Cycle 4
Time to ANC nadir was defined as the time from chemotherapy administration until the occurrence of the ANC nadir.
Time frame: Cycle 4 (each cycle was 21 days)
Percentage of Participants With Febrile Neutropenia (FN) Across All Cycles From Cycle 1 to Cycle 4
FN was defined as a temperature of more than 38.2 degree Celsius (°C) concurrent with an ANC greater than 0.5×10\^9/L..
Time frame: Cycle 1 to Cycle 4 (each cycle was 21 days)
Number of Participants With Worst Grade Adverse Events (AEs), Deaths, Other Serious Adverse Events (SAEs), and Other AEs Leading to Discontinuation From Study Therapy, and Worst Grade Laboratory Abnormalities
An AE was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. An SAE was an AE resulting in any of following outcomes or deemed significant for any other reason: death, initial or prolonged inpatient hospitalization, life-threatening experience (immediate risk of dying), persistent or significant disability or incapacity, congenital anomaly. Participants with SAE other than death were reported.AE and Laboratory Abnormalities ("Hematology and Chemistry") were collected and graded as per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 4.03, where Grade 3 refers to severe or medically significant but not immediately life threatening; hospitalization or prolongation of hospitalization indicated and Grade 4 refers to life-threatening consequences; urgent intervention indicated.
Time frame: From the first dose up to 30 days post last dose of study drug (up to 4 months)
Percentage of Participants With Hospitalization Across All Cycles From Cycle 1 to Cycle 4
Time frame: All cycles from Cycle 1 to Cycle 4 (each cycle was 21 days)
Number of Participants With Positive Antibodies for SPI-2012
Serum samples were to be tested in a screening assay for antibodies binding to SPI-2012 using a validated enzyme-linked immunosorbent assay (ELISA). Any serum samples positive for the antibody were to be tested in a confirmatory competitive inhibition assay using two antigens, SPI-2012 or granulocyte colony-stimulating factor (G-CSF), to confirm the presence of antibodies binding to SPI-2012 and to identify samples that were positive for antibodies binding to G-CSF.
Time frame: Up to the end of the study (Approximately 3.5 months)
Time to Reach Maximum Concentration of SPI-2012 (Tmax)
Blood samples were collected at specific time points to determine the serum concentrations of SPI-2012 and to derive pharmacokinetic (PK) parameters.
Time frame: Pre-dose and at 1, 3, 6, 8, 10, 24, 48, 72, 144, 192, and 312 hours post-dose in Cycle 1 (each cycle was 21 days)
Maximum Concentration of SPI-2012 (Cmax)
Blood samples were collected at specific time points to determine the serum concentrations of SPI-2012 and to derive PK parameters.
Time frame: Pre-dose and at 1, 3, 6, 8, 10, 24, 48, 72, 144, 192, and 312 hours post-dose in Cycle 1 (each cycle was 21 days)
Area Under the Serum Concentration-Time Curve From Time Zero to 312 Hours Post-Dose (AUC0-312)
AUC(0-312) is the area under the serum concentration-time curve from time zero to 312 hour post dose calculated by the linear trapezoidal rule. Blood samples were collected at specific time points to determine the serum concentrations of SPI-2012 and to derive PK parameters.
Time frame: Pre-dose and at 1, 3, 6, 8, 10, 24, 48, 72, 144, 192, and 312 hours post-dose in Cycle 1 (each cycle was 21 days)
Half-life of SPI-2012 (t1/2)
t1/2 data were calculated and reported as harmonic mean and pseudo standard deviation (SD). Blood samples were collected at specific time points to determine the serum concentrations of SPI-2012 and to derive PK parameters.
Time frame: Pre-dose and at 1, 3, 6, 8, 10, 24, 48, 72, 144, 192, and 312 hours post-dose in Cycle 1 (each cycle was 21 days)
Participants were enrolled at 27 investigative sites in the United States (10 sites), Australia (5 sites), Georgia (2 sites), Hungary (5 sites), Israel (1 site), and Poland (4 sites) from 25 March 2013 to 12 August 2014.
| Milestone | Arm 1: SPI-2012 45 µg/kg and Docetaxel + Cyclophosphamide (TC) | Arm 2: SPI-2012 135 µg/kg and TC | Arm 3: SPI-2012 270 µg/kg and TC | Arm 4: Pegfilgrastim and TC |
|---|---|---|---|---|
| Started | 39 | 37 | 36 | 36 |
| Evaluable population | 39 | 36 | 36 | 36 |
| Completed | 38 | 32 | 33 | 35 |
| Not completed | 1 | 5 | 3 | 1 |
| Withdrew: Adverse event | 0 | 0 | 1 | 1 |
| Withdrew: Initiation of non-protocol therapy either for progressive disease or intolerance of tc regimen | 0 | 2 | 0 | 0 |
| Withdrew: Investigator's discretion | 0 | 1 | 1 | 0 |
| Withdrew: Need for chemotherapy or chemotherapy regimen was changed due to amended her2 status | 1 | 0 | 0 | 0 |
| Withdrew: Participant refused further treatment or withdrew consent | 0 | 2 | 1 | 0 |
DSN was defined as the interval from the day of first observation of severe neutropenia (ANC \<0.5\*10\^9/L, Grade 4 neutropenia per NCI CTCAE) to the first ANC recovery to =\> 2.0\*10\^9/L in Cycle 1.
| days | Arm 1: SPI-2012 45 µg/kg and TC | Arm 2: SPI-2012 135 µg/kg and TC | Arm 3: SPI-2012 270 µg/kg and TC | Arm 4: Pegfilgrastim and TC |
|---|---|---|---|---|
| Duration of Severe Neutropenia (DSN) in Cycle 1 | 1.03 ± 1.547 | 0.44 ± 1.275 | 0.03 ± 0.167 | 0.31 ± 0.822 |
DSN was defined as the interval from the day of first observation of severe neutropenia (ANC \<0.5\*10\^9/L, Grade 4 neutropenia per NCI CTCAE) to the first ANC recovery to =\> 2.0\*10\^9/L in Cycle 2.
| days | Arm 1: SPI-2012 45 µg/kg and TC | Arm 2: SPI-2012 135 µg/kg and TC | Arm 3: SPI-2012 270 µg/kg and TC | Arm 4: Pegfilgrastim and TC |
|---|---|---|---|---|
| Duration of DSN in Cycle 2 | 0.46 ± 1.022 | 0.12 ± 0.478 | 0.03 ± 0.171 | 0.08 ± 0.368 |
DSN was defined as the interval from the day of first observation of severe neutropenia (ANC \<0.5\*10\^9/L, Grade 4 neutropenia per NCI CTCAE) to the first ANC recovery to =\> 2.0\*10\^9/L in Cycle 3.
| days | Arm 1: SPI-2012 45 µg/kg and TC | Arm 2: SPI-2012 135 µg/kg and TC | Arm 3: SPI-2012 270 µg/kg and TC | Arm 4: Pegfilgrastim and TC |
|---|---|---|---|---|
| Duration of DSN in Cycle 3 | 0.45 ± 1.132 | 0.16 ± 0.628 | 0.15 ± 0.610 | 0.14 ± 0.593 |
DSN was defined as the interval from the day of first observation of severe neutropenia (ANC \<0.5\*10\^9/L, Grade 4 neutropenia per NCI CTCAE) to the first ANC recovery to =\> 2.0\*10\^9/L in Cycle 4.
| days | Arm 1: SPI-2012 45 µg/kg and TC | Arm 2: SPI-2012 135 µg/kg and TC | Arm 3: SPI-2012 270 µg/kg and TC | Arm 4: Pegfilgrastim and TC |
|---|---|---|---|---|
| Duration of DSN in Cycle 4 | 1.05 ± 4.579 | 0.19 ± 0.738 | 0.09 ± 0.522 | 0.11 ± 0.404 |
Time to ANC recovery was defined as the time from chemotherapy administration until ANC increased to ≥ 2×10\^9/L after the expected nadir within Cycle 1. Time to ANC recovery was not calculated for participants whose ANC value didn't drop below 2 x10\^9/L within Cycle 1.
| days | Arm 1: SPI-2012 45 µg/kg and TC | Arm 2: SPI-2012 135 µg/kg and TC | Arm 3: SPI-2012 270 µg/kg and TC | Arm 4: Pegfilgrastim and TC |
|---|---|---|---|---|
| Time to ANC Recovery in Cycle 1 | 10.0 (10.0 to 11.0) | 8.5 (8.0 to 9.0) | 8.0 (7.0 to 9.0) | 9.0 (8.0 to 10.0) |
Time to ANC recovery was defined as the time from chemotherapy administration until ANC increased to ≥2×10\^9/L after the expected nadir within Cycle 2. Time to ANC recovery was not calculated for participants whose ANC value didn't drop below 2 x10\^9/L within Cycle 2.
| days | Arm 1: SPI-2012 45 µg/kg and TC | Arm 2: SPI-2012 135 µg/kg and TC | Arm 3: SPI-2012 270 µg/kg and TC | Arm 4: Pegfilgrastim and TC |
|---|---|---|---|---|
| Time to ANC Recovery in Cycle 2 | 11.0 (10.0 to 11.0) | 9.5 (8.0 to 10.0) | 10.0 (8.0 to 14.0) | 10.0 (8.0 to 11.0) |
Time to ANC recovery was defined as the time from chemotherapy administration until ANC increased to ≥2×10\^9/L after the expected nadir within Cycle 3. Time to ANC recovery was not calculated for participants whose ANC value didn't drop below 2 x10\^9/L within Cycle 3.
| days | Arm 1: SPI-2012 45 µg/kg and TC | Arm 2: SPI-2012 135 µg/kg and TC | Arm 3: SPI-2012 270 µg/kg and TC | Arm 4: Pegfilgrastim and TC |
|---|---|---|---|---|
| Time to ANC Recovery in Cycle 3 | 10.0 (10.0 to 11.0) | 9.5 (8.0 to 12.0) | 9.0 (8.0 to 13.0) | 10.0 (9.0 to 11.0) |
Time to ANC recovery was defined as the time from chemotherapy administration until ANC increased to ≥2×10\^9/L after the expected nadir within Cycle 4. Time to ANC recovery was not calculated for participants whose ANC value didn't drop below 2 x10\^9/L within Cycle 4.
| days | Arm 1: SPI-2012 45 µg/kg and TC | Arm 2: SPI-2012 135 µg/kg and TC | Arm 3: SPI-2012 270 µg/kg and TC | Arm 4: Pegfilgrastim and TC |
|---|---|---|---|---|
| Time to ANC Recovery in Cycle 4 | 11.0 (10.0 to 13.0) | 10.0 (9.0 to 11.0) | 10.0 (8.0 to 14.0) | 10.0 (8.0 to 11.0) |
Mean ANC nadir was defined as the mean of the lowest ANC value (\*10\^9/L) after administration of the study drug (SPI-2012 or pegfilgrastim) on any day in Days 1-3 of Cycle 1.
| 10^9 ANC per liter | Arm 1: SPI-2012 45 µg/kg and TC | Arm 2: SPI-2012 135 µg/kg and TC | Arm 3: SPI-2012 270 µg/kg and TC | Arm 4: Pegfilgrastim and TC |
|---|---|---|---|---|
| Absolute Neutrophil Count (ANC) Nadir Overtime in Cycle 1 | 1.5 ± 1.77 | 4.0 ± 3.86 | 7.2 ± 5.47 | 3.2 ± 2.43 |
Mean ANC nadir was defined as the mean of the lowest ANC value (\*10\^9/L) after administration of the study drug (SPI-2012 or pegfilgrastim) on any day in Days 1-3 of Cycle 2.
| 10^9 ANC/L | Arm 1: SPI-2012 45 µg/kg and TC | Arm 2: SPI-2012 135 µg/kg and TC | Arm 3: SPI-2012 270 µg/kg and TC | Arm 4: Pegfilgrastim and TC |
|---|---|---|---|---|
| Absolute ANC Nadir Overtime in Cycle 2 | 2.0 ± 1.89 | 3.9 ± 2.55 | 6.8 ± 6.30 | 3.3 ± 2.16 |
Mean ANC nadir was defined as the mean of the lowest ANC value (\*10\^9/L) after administration of the study drug (SPI-2012 or pegfilgrastim) on any day in Days 1-3 of Cycle 3.
| 10^9 ANC/L | Arm 1: SPI-2012 45 µg/kg and TC | Arm 2: SPI-2012 135 µg/kg and TC | Arm 3: SPI-2012 270 µg/kg and TC | Arm 4: Pegfilgrastim and TC |
|---|---|---|---|---|
| Absolute ANC Nadir Overtime in Cycle 3 | 2.3 ± 1.87 | 4.4 ± 3.26 | 6.1 ± 4.81 | 3.5 ± 1.92 |
Mean ANC nadir was defined as the mean of the lowest ANC value (\*10\^9/L) after administration of the study drug (SPI-2012 or pegfilgrastim) on any day in Days 1-3 of Cycle 4.
| 10^9 ANC/L | Arm 1: SPI-2012 45 µg/kg and TC | Arm 2: SPI-2012 135 µg/kg and TC | Arm 3: SPI-2012 270 µg/kg and TC | Arm 4: Pegfilgrastim and TC |
|---|---|---|---|---|
| Absolute ANC Nadir Overtime in Cycle 4 | 2.1 ± 2.12 | 4.1 ± 2.86 | 4.8 ± 3.00 | 2.7 ± 1.64 |
Depth of ANC nadir was defined as the lowest Median ANC value (\*10\^9/L) after administration of the study drug (SPI-2012 or pegfilgrastim) on any day in Days 1-3 of Cycle 1.
| 10^9 ANC/L | Arm 1: SPI-2012 45 µg/kg and TC | Arm 2: SPI-2012 135 µg/kg and TC | Arm 3: SPI-2012 270 µg/kg and TC | Arm 4: Pegfilgrastim and TC |
|---|---|---|---|---|
| Depth of ANC Nadir in Cycle 1 | 0.8 (0.0 to 9.0) | 3.0 (0.1 to 14.1) | 6.2 (0.2 to 21.0) | 3.0 (0.0 to 9.1) |
Depth of ANC nadir was defined as the lowest Median ANC value (\*10\^9/L) after administration of the study drug (SPI-2012 or pegfilgrastim) on any day in Days 1-3 of Cycle 2.
| 10^9 ANC/L | Arm 1: SPI-2012 45 µg/kg and TC | Arm 2: SPI-2012 135 µg/kg and TC | Arm 3: SPI-2012 270 µg/kg and TC | Arm 4: Pegfilgrastim and TC |
|---|---|---|---|---|
| Depth of ANC Nadir in Cycle 2 | 1.3 (0.1 to 8.0) | 3.3 (0.1 to 9.5) | 4.8 (0.3 to 25.7) | 2.9 (0.1 to 9.2) |
Depth of ANC nadir was defined as the lowest Median ANC value (\*10\^9/L) after administration of the study drug (SPI-2012 or pegfilgrastim) on any day in Days 1-3 of Cycle 3.
| 10^9 ANC/L | Arm 1: SPI-2012 45 µg/kg and TC | Arm 2: SPI-2012 135 µg/kg and TC | Arm 3: SPI-2012 270 µg/kg and TC | Arm 4: Pegfilgrastim and TC |
|---|---|---|---|---|
| Depth of ANC Nadir in Cycle 3 | 1.9 (0.0 to 7.3) | 3.4 (0.1 to 12.3) | 4.1 (0.2 to 21.4) | 3.5 (0.1 to 8.1) |
Depth of ANC nadir was defined as the lowest Median ANC value (\*10\^9/L) after administration of the study drug (SPI-2012 or pegfilgrastim) on any day in Days 1-3 of Cycle 4.
| 10^9 ANC/L | Arm 1: SPI-2012 45 µg/kg and TC | Arm 2: SPI-2012 135 µg/kg and TC | Arm 3: SPI-2012 270 µg/kg and TC | Arm 4: Pegfilgrastim and TC |
|---|---|---|---|---|
| Depth of ANC Nadir in Cycle 4 | 8.0 (0.0 to 9.2) | 4.2 (0.1 to 11.2) | 4.2 (0.4 to 11.9) | 2.4 (0.1 to 6.4) |
Time to ANC nadir was defined as the time from chemotherapy administration until the occurrence of the ANC nadir.
| Days | Arm 1: SPI-2012 45 µg/kg and TC | Arm 2: SPI-2012 135 µg/kg and TC | Arm 3: SPI-2012 270 µg/kg and TC | Arm 4: Pegfilgrastim and TC |
|---|---|---|---|---|
| Time to ANC Nadir in Cycle 1 | 8.0 (7.0 to 8.0) | 7.0 (7.0 to NA) | 7.0 (7.0 to 8.0) | 7.5 (7.0 to 16.0) |
Time to ANC nadir was defined as the time from chemotherapy administration until the occurrence of the ANC nadir.
| days | Arm 1: SPI-2012 45 µg/kg and TC | Arm 2: SPI-2012 135 µg/kg and TC | Arm 3: SPI-2012 270 µg/kg and TC | Arm 4: Pegfilgrastim and TC |
|---|---|---|---|---|
| Time to ANC Nadir in Cycle 2 | 8.0 (8.0 to NA) | 7.0 (7.0 to 8.0) | 8.0 (7.0 to 10.0) | 8.0 (7.0 to 15.0) |
Time to ANC nadir was defined as the time from chemotherapy administration until the occurrence of the ANC nadir.
| days | Arm 1: SPI-2012 45 µg/kg and TC | Arm 2: SPI-2012 135 µg/kg and TC | Arm 3: SPI-2012 270 µg/kg and TC | Arm 4: Pegfilgrastim and TC |
|---|---|---|---|---|
| Time to ANC Nadir in Cycle 3 | 8.0 (8.0 to NA) | 7.0 (7.0 to 8.0) | 8.0 (7.0 to 9.0) | 8.0 (7.0 to 15.0) |
Time to ANC nadir was defined as the time from chemotherapy administration until the occurrence of the ANC nadir.
| days | Arm 1: SPI-2012 45 µg/kg and TC | Arm 2: SPI-2012 135 µg/kg and TC | Arm 3: SPI-2012 270 µg/kg and TC | Arm 4: Pegfilgrastim and TC |
|---|---|---|---|---|
| Time to ANC Nadir in Cycle 4 | 8.0 (8.0 to NA) | 8.0 (7.0 to 8.0) | 8.0 (7.0 to 21.0) | 8.0 (7.0 to 8.0) |
FN was defined as a temperature of more than 38.2 degree Celsius (°C) concurrent with an ANC greater than 0.5×10\^9/L..
| percentage of participants | Arm 1: SPI-2012 45 µg/kg and TC | Arm 2: SPI-2012 135 µg/kg and TC | Arm 3: SPI-2012 270 µg/kg and TC | Arm 4: Pegfilgrastim and TC |
|---|---|---|---|---|
| Percentage of Participants With Febrile Neutropenia (FN) Across All Cycles From Cycle 1 to Cycle 4 | 7.7 | 2.8 | 2.8 | 5.6 |
An AE was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. An SAE was an AE resulting in any of following outcomes or deemed significant for any other reason: death, initial or prolonged inpatient hospitalization, life-threatening experience (immediate risk of dying), persistent or significant disability or incapacity, congenital anomaly. Participants with SAE other than death were reported.AE and Laboratory Abnormalities ("Hematology and Chemistry") were collected and graded as per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 4.03, where Grade 3 refers to severe or medically significant but not immediately life threatening; hospitalization or prolongation of hospitalization indicated and Grade 4 refers to life-threatening consequences; urgent intervention indicated.
| Participants | Arm 1: SPI-2012 45 µg/kg and TC | Arm 2: SPI-2012 135 µg/kg and TC | Arm 3: SPI-2012 270 µg/kg and TC | Arm 4: Pegfilgrastim and TC |
|---|---|---|---|---|
| Grade 3-4 TEAEs | 24 | 12 | 13 | 12 |
| Death | 0 | 0 | 0 | 0 |
| SAEs Other Than Death | 5 | 4 | 2 | 8 |
| TEAEs Leading to Discontinuation From Study Therapy | 0 | 2 | 1 | 1 |
| Grade 3-4 Lab Abnormalities: Hematology | 33 | 19 | 18 | 28 |
| Grade 3-4 Lab Abnormalities: Chemistry | 8 | 4 | 6 | 8 |
| percentage of participants | Arm 1: SPI-2012 45 µg/kg and TC | Arm 2: SPI-2012 135 µg/kg and TC | Arm 3: SPI-2012 270 µg/kg and TC | Arm 4: Pegfilgrastim and TC |
|---|---|---|---|---|
| Percentage of Participants With Hospitalization Across All Cycles From Cycle 1 to Cycle 4 | 7.7 | 8.3 | 2.8 | 13.9 |
Serum samples were to be tested in a screening assay for antibodies binding to SPI-2012 using a validated enzyme-linked immunosorbent assay (ELISA). Any serum samples positive for the antibody were to be tested in a confirmatory competitive inhibition assay using two antigens, SPI-2012 or granulocyte colony-stimulating factor (G-CSF), to confirm the presence of antibodies binding to SPI-2012 and to identify samples that were positive for antibodies binding to G-CSF.
| Participants | Arm 1: SPI-2012 45 µg/kg and TC | Arm 2: SPI-2012 135 µg/kg and TC | Arm 3: SPI-2012 270 µg/kg and TC |
|---|---|---|---|
| Number of Participants With Positive Antibodies for SPI-2012 | 0 | 0 | 2 |
Blood samples were collected at specific time points to determine the serum concentrations of SPI-2012 and to derive pharmacokinetic (PK) parameters.
| hours (hrs) | Arm 1: SPI-2012 45 µg/kg and TC | Arm 2: SPI-2012 135 µg/kg and TC | Arm 3: SPI-2012 270 µg/kg and TC |
|---|---|---|---|
| Time to Reach Maximum Concentration of SPI-2012 (Tmax) | 58.7 (46.9 to 70.5) | 9.00 (8 to 48.1) | 24.0 (24 to 24.1) |
Blood samples were collected at specific time points to determine the serum concentrations of SPI-2012 and to derive PK parameters.
| nanograms per milliliter (ng/mL) | Arm 1: SPI-2012 45 µg/kg and TC | Arm 2: SPI-2012 135 µg/kg and TC | Arm 3: SPI-2012 270 µg/kg and TC |
|---|---|---|---|
| Maximum Concentration of SPI-2012 (Cmax) | 7.00 ± 6.08 | 247 ± 276 | 299 ± 329 |
AUC(0-312) is the area under the serum concentration-time curve from time zero to 312 hour post dose calculated by the linear trapezoidal rule. Blood samples were collected at specific time points to determine the serum concentrations of SPI-2012 and to derive PK parameters.
| nanogram*hour per milliliter (ng*hr/mL) | Arm 1: SPI-2012 45 µg/kg and TC | Arm 2: SPI-2012 135 µg/kg and TC | Arm 3: SPI-2012 270 µg/kg and TC |
|---|---|---|---|
| Area Under the Serum Concentration-Time Curve From Time Zero to 312 Hours Post-Dose (AUC0-312) | — | 16000 ± 5850 | 22900 ± 25100 |
t1/2 data were calculated and reported as harmonic mean and pseudo standard deviation (SD). Blood samples were collected at specific time points to determine the serum concentrations of SPI-2012 and to derive PK parameters.
| hrs | Arm 1: SPI-2012 45 µg/kg and TC | Arm 2: SPI-2012 135 µg/kg and TC | Arm 3: SPI-2012 270 µg/kg and TC |
|---|---|---|---|
| Half-life of SPI-2012 (t1/2) | — | 81.0 ± 88.4 | 31.5 ± NA |
Collected over From the first dose up to 30 days post last dose of study drug (up to 4 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm 1: SPI-2012 45 µg/kg and TC | 0/39 (0%) | 5/39 (12.8%) | 36/39 (92.3%) |
| Arm 2: SPI-2012 135 µg/kg and TC | 0/37 (0%) | 4/37 (10.8%) | 33/37 (89.2%) |
| Arm 3: SPI-2012 270 µg/kg and TC | 0/36 (0%) | 2/36 (5.6%) | 33/36 (91.7%) |
| Arm 4: Pegfilgrastim and TC | 0/36 (0%) | 8/36 (22.2%) | 35/36 (97.2%) |
| Event | Arm 1: SPI-2012 45 µg/kg and TC | Arm 2: SPI-2012 135 µg/kg and TC | Arm 3: SPI-2012 270 µg/kg and TC | Arm 4: Pegfilgrastim and TC |
|---|---|---|---|---|
| PyrexiaGeneral disorders | 0/39 | 0/37 | 0/36 | 2/36 |
| Febrile neutropeniaBlood and lymphatic system disorders | 2/39 | 1/37 | 1/36 | 1/36 |
| Atrial fibrillationCardiac disorders | 0/39 | 0/37 | 0/36 | 1/36 |
| DiverticulitisInfections and infestations | 1/39 | 0/37 | 1/36 | 0/36 |
| Back painMusculoskeletal and connective tissue disorders | 0/39 | 0/37 | 0/36 | 1/36 |
| Vaginal haemorrhageReproductive system and breast disorders | 0/39 | 0/37 | 0/36 | 1/36 |
| UrticariaSkin and subcutaneous tissue disorders | 0/39 | 0/37 | 0/36 | 1/36 |
| CellulitisInfections and infestations | 0/39 | 0/37 | 0/36 | 1/36 |
| Non-cardiac chest painGeneral disorders | 0/39 | 1/37 | 0/36 | 0/36 |
| Gastritis viralInfections and infestations | 0/39 | 1/37 | 0/36 | 0/36 |
| Event | Arm 1: SPI-2012 45 µg/kg and TC | Arm 2: SPI-2012 135 µg/kg and TC | Arm 3: SPI-2012 270 µg/kg and TC | Arm 4: Pegfilgrastim and TC |
|---|---|---|---|---|
| FatigueGeneral disorders | 24/39 | 11/37 | 19/36 | 20/36 |
| AlopeciaSkin and subcutaneous tissue disorders | 21/39 | 18/37 | 12/36 | 13/36 |
| NauseaGastrointestinal disorders | 19/39 | 12/37 | 15/36 | 16/36 |
| DiarrhoeaGastrointestinal disorders | 17/39 | 7/37 | 14/36 | 15/36 |
| Bone painMusculoskeletal and connective tissue disorders | 9/39 | 10/37 | 12/36 | 13/36 |
| HeadacheNervous system disorders | 12/39 | 5/37 | 8/36 | 9/36 |
| InsomniaPsychiatric disorders | 3/39 | 5/37 | 5/36 | 11/36 |
| AstheniaGeneral disorders | 5/39 | 2/37 | 5/36 | 8/36 |
The Evaluable Population included all randomized participants who had received either SPI-2012 or pegfilgrastim and had completed Cycle 1.
| Age, Continuous(years) | Arm 1: SPI-2012 45 µg/kg and TC | Arm 2: SPI-2012 135 µg/kg and TC | Arm 3: SPI-2012 270 µg/kg and TC | Arm 4: Pegfilgrastim and TC | Total |
|---|---|---|---|---|---|
| Mean | 59.8 ± 11.31 | 56.8 ± 10.63 | 55.7 ± 9.79 | 60.4 ± 10.43 | 58.2 ± 10.64 |
| Sex: Female, Male(Participants) | Arm 1: SPI-2012 45 µg/kg and TC | Arm 2: SPI-2012 135 µg/kg and TC | Arm 3: SPI-2012 270 µg/kg and TC | Arm 4: Pegfilgrastim and TC | Total |
|---|---|---|---|---|---|
| Female | 39 | 35 | 34 | 36 | 144 |
| Male | 0 | 1 | 2 | 0 | 3 |
| Ethnicity (NIH/OMB)(Participants) | Arm 1: SPI-2012 45 µg/kg and TC | Arm 2: SPI-2012 135 µg/kg and TC | Arm 3: SPI-2012 270 µg/kg and TC | Arm 4: Pegfilgrastim and TC | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 6 | 2 | 2 | 4 | 14 |
| Not Hispanic or Latino | 33 | 34 | 34 | 32 | 133 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Arm 1: SPI-2012 45 µg/kg and TC | Arm 2: SPI-2012 135 µg/kg and TC | Arm 3: SPI-2012 270 µg/kg and TC | Arm 4: Pegfilgrastim and TC | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 0 | 0 | 1 |
| Asian | 0 | 0 | 1 | 0 | 1 |
| Black or African American | 2 | 0 | 0 | 0 | 2 |
| White | 36 | 36 | 35 | 32 | 139 |
| Others | 0 | 0 | 0 | 4 | 4 |
Plan to share: No
Ran from Mar 2013 to primary completion in Aug 2014, 16 months.
Results were first posted in Apr 2022, 7 years 8 months after primary completion. A results delay was requested in Jan 2020.
Of 25 phase 2 interventional studies under Neutropenia, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 41. This study's 16 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Eflapegrastim · Pegfilgrastim
Spectrum Pharmaceuticals, Inc →